Clinical considerations for an effective medical therapy in Wilson's disease

Annals of the New York Academy of Sciences

Volumn 1315, Issue 1, 2014, Pages 81-85

  Weiss, Karl Heinz ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

ATP7B; d penicilamine; Trientine; TTM; Wilson's disease

Indexed keywords

CHELATING AGENT; COPPER; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC DERIVATIVE;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CHELATION THERAPY; CHEMICAL REACTION; CLINICAL EFFECTIVENESS; COPPER METABOLISM; DRUG EFFICACY; HUMAN; LIVER DISEASE; MEDICATION COMPLIANCE; NEUROLOGIC DISEASE; RATING SCALE; STANDARDIZATION; TREATMENT RESPONSE; WILSON DISEASE;

ATP7B; D-PENICILAMINE; TRIENTINE; TTM; WILSON'S DISEASE;

CERULOPLASMIN; CHELATING AGENTS; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; MOLYBDENUM; PENICILLAMINE; TRIENTINE; ZINC;

EID: 84899996640     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12437     Document Type: Article

References (51)

1. Ferenci, P., P. Steindl-Munda, W. Vogel, et al. 2005. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin. Gastroenterol. Hepatol. 3: 811-818.
2. Ferenci, P., K. Caca, G. Loudianos, et al. 2003. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 23: 139-142.
3. Ala, A., A.P. Walker, K. Ashkan, et al. 2007. Wilson's disease. Lancet. 369: 397-408.
4. Weiss, K.H., M. Schafer, D.N. Gotthardt, et al. 2013. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin. Transplant. 27: 914-922.
5. Weiss, K.H., D. Gotthardt, J. Schmidt, et al. 2007. Liver transplantation for metabolic liver diseases in adults: indications and outcome. Nephrol. Dial. Transplant. 22(Suppl 8): viii9-viii12.
6. Beinhardt, S., W. Leiss, A.F. Stattermayer, et al. 2014. Long-term outcomes of patients with Wilson Disease in a large Austrian cohort. Clin. Gastroenterol. Hepatol. 12: 683-689.
7. Bruha, R., Z. Marecek, L. Pospisilova, et al. 2011. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int. 31: 83-91.
8. Stremmel, W., K.W. Meyerrose, C. Niederau, et al. 1991. Wilson disease: clinical presentation, treatment, and survival. Ann. Intern. Med. 115: 720-726.
9. Holscher, S., B. Leinweber, H. Hefter, et al. 2010. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur. Neurol. 64: 83-87.
10. 2012. EASL Clinical Practice Guidelines: Wilson's disease. J. Hepatol. 56: 671-685.
11. Roberts, E.A. & M.L. Schilsky. 2008. Diagnosis and treatment of Wilson disease: an update. Hepatology 47: 2089-2111.
12. Walshe, J.M. & A.K. Dixon. 1986. Dangers of non-compliance in Wilson's disease. Lancet 1: 845-847.
13. Scheinberg, I.H., M.E. Jaffe & I. Sternlieb. 1987. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N. Engl. J. Med. 317: 209-213.
14. Dziezyc, K., M. Karlinski, T. Litwin & A. Czlonkowska. 2014. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. Eur. J. Neurol. 21: 332-337.
15. Weiss, K.H. & W. Stremmel. 2012. Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr. Gastroenterol. Rep. 14: 1-7.
16. Merle, U., M. Schaefer, P. Ferenci & W. Stremmel. 2007. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 56: 115-120.
17. Weiss, K.H., D.N. Gotthardt, D. Klemm, et al. 2011. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 140: 1189-1198, e1181.
18. Weiss, K.H., F. Thurik, D.N. Gotthardt, et al. 2013. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin. Gastroenterol. Hepatol. 11: 1028-1035, e1021-e1022.
19. Czlonkowska, A., J. Gajda & M. Rodo. 1996. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J. Neurol. 243: 269-273.
20. Arnon, R., J.F. Calderon, M. Schilsky, et al. 2007. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J. Pediatr. Gastroenterol. Nutr. 44: 596-602.
21. Linn, F.H., R.H. Houwen, J. van Hattum, et al. 2009. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 50: 1442-1452.
22. Brewer, G.J., G. Hill, A. Prasad & R. Dick. 1987. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Proc. Soc. Exp. Biol. Med. 184: 446-455.
23. Fox, A.N. & M. Schilsky. 2008. Once daily trientine for maintenance therapy of Wilson disease. Am. J. Gastroenterol. 103: 494-495.
24. Walshe, J.M. 2013. The acute haemolytic syndrome in Wilson's disease-a review of 22 patients. QJM. 106: 1003-1008.
25. Nazer, H., R.J. Ede, A.P. Mowat & R. Williams. 1986. Wilson's disease: clinical presentation and use of prognostic index. Gut 27: 1377-1381.
26. Dhawan, A., R.M. Taylor, P. Cheeseman, et al. 2005. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 11: 441-448.
27. Brewer, G.J., V. Yuzbasiyan-Gurkan, V. Johnson, et al. 1993. Treatment of Wilson's disease with zinc XII: dose regimen requirements. Am. J. Med. Sci. 305: 199-202.
28. Hill, G.M., G.J. Brewer, J.E. Juni, et al. 1986. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am. J. Med. Sci. 292: 344-349.
29. Brewer, G.J., R.D. Dick, V.D. Johnson, et al. 1998. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J. Lab. Clin. Med. 132: 264-278.
30. Brewer, G.J., F. Askari, M.T. Lorincz, et al. 2006. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol. 63: 521-527.
31. Brewer, G.J., C.A. Terry, A.M. Aisen & G.M. Hill. 1987. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch. Neurol. 44: 490-493.
32. Walshe, J.M. 2012. Serum 'free' copper in Wilson disease. QJM. 105: 419-423.
33. Lang, P.A., M. Schenck, J.P. Nicolay, et al. 2007. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat. Med. 13: 164-170.
34. Zischka, H., J. Lichtmannegger, S. Schmitt, et al. 2011. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J. Clin. Invest. 121: 1508-1518.
35. Walshe, J.M. 1963. Filterable and non-filterable serum copper. 1. The action of penicillamine. Clin. Sci. 25: 405-411.
36. Stuerenburg, H.J. 2000. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J. Neural Transm. 107: 321-329.
37. Chen, D.B., L. Feng, X.P. Lin, et al. 2012. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS One 7: e37709.
38. Brewer, G.J., F. Askari, R.B. Dick, et al. 2009. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl. Res. 154: 70-77.
39. Merle, U., C. Eisenbach, K.H. Weiss, et al. 2009. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J. Hepatol. 51: 925-930.
40. Walshe, J.M. 2003. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann. Clin. Biochem. 40(Pt 2): 115-121.
41. Trocello, J.M., S.E. Balkhi, F. Woimant, et al. 2014. Relative exchangeable copper: a promising tool for family screening in Wilson disease. Mov. Disord. 29: 558-562.
42. Schmitt, F., G. Podevin, J. Poupon, et al. 2013. Evolution of exchangeable copper and relative exchangeable copper through the course of Wilson's disease in the Long Evans Cinnamon rat. PLoS One 8: e82323.
43. El Balkhi, S., J.M. Trocello, J. Poupon, et al. 2011. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson's disease diagnosis. Clin. Chim. Acta. 412: 2254-2260.
44. El Balkhi, S., J. Poupon, J.M. Trocello, et al. 2009. Determination of ultrafiltrable and exchangeable copper in plasma: stability and reference values in healthy subjects. Anal. Bioanal. Chem. 394: 1477-1484.
45. Buckley, W.T. & R.A. Vanderpool. 2008. Analytical variables affecting exchangeable copper determination in blood plasma. Biometals 21: 601-612.
46. Walshe, J.M. 2011. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease. QJM. 104: 775-778.
47. Brewer, G.J., P. Hedera, K.J. Kluin, et al. 2003. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 60: 379-385.
48. Brewer, G.J., V. Johnson, R.D. Dick, et al. 1996. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 53: 1017-1025.
49. Czlonkowska, A., B. Tarnacka, J.C. Moller, et al. 2007. Unified Wilson's disease rating scale-a proposal for the neurological scoring of Wilson's disease patients. Neurol. Neurochir. Pol. 41: 1-12.
50. Aggarwal, A., N. Aggarwal, A. Nagral, et al. 2009. A novel global assessment scale for Wilson's disease (GAS for WD). Mov. Disord. 24: 509-518.
51. Leinweber, B., J.C. Moller, A. Scherag, et al. 2008. Evaluation of the unified Wilson's disease rating scale (UWDRS) in German patients with treated Wilson's disease. Mov. Disord. 23: 54-62.